- Home
- RM vs MNPR Comparison
RM vs MNPR Comparison
Compare RM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RM | MNPR |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.4M | 368.9M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RM | MNPR |
|---|---|---|
| Price | $38.26 | $57.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $30.00 | ★ $107.00 |
| AVG Volume (30 Days) | 46.4K | ★ 174.1K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | 7.49 | ★ 54.99 |
| EPS | ★ 4.45 | N/A |
| Revenue | ★ $645,598,000.00 | N/A |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $8.78 | N/A |
| P/E Ratio | $8.53 | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $26.06 | $28.40 |
| 52 Week High | $46.00 | $105.00 |
Technical Indicators
Market Signals| Indicator | RM | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 74.45 | 51.64 |
| Support Level | $37.78 | $56.15 |
| Resistance Level | $39.22 | $60.87 |
| Average True Range (ATR) | 1.12 | 3.81 |
| MACD | 0.68 | 0.38 |
| Stochastic Oscillator | 93.47 | 69.61 |
Price Performance
Historical ComparisonAbout RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.